Antibiotic choice and methicillin-resistant Staphylococcus aureus rate in children hospitalized for atopic dermatitis

Wang, Vivian; Keefer, Matthew L.; Ong, Peck Y.

doi:10.1016/j.anai.2018.12.001

Cited by 27 publications

(27 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…MSSA and MRSA cause an equal proportion of infectious complications (40% each) in hospitalized children with AD. 4 These infection rates are consistent with that of the general pediatric inpatient populations across the United States. 24 The second most common cause of SSTI and systemic infections in AD is Streptococcus pyogenes .…”

Section: Bacterial Infectionssupporting

confidence: 78%

“… 28 However, apart from the outcome of AD severity, there may be a subset of patients with severe AD exacerbation who may benefit from antibiotics in terms of infections or the prevention of infectious complications. 4 , 28 , 29 It has been proposed that these patients may be differentiated by a higher density of S aureus and the amount of tissue damage caused by S aureus –host interaction. 29 Children with severe AD exacerbation were found to have elevated C-reactive protein and erythrocyte sedimentation rate, although these levels were significantly less than that of patients with infectious complications.…”

Section: Bacterial Infectionsmentioning

confidence: 99%

“… 29 Children with severe AD exacerbation were found to have elevated C-reactive protein and erythrocyte sedimentation rate, although these levels were significantly less than that of patients with infectious complications. 4 There may be a potential use in these inflammatory markers in identifying patients with AD who are at risk for severe infectious complications.

Figure 2 Impetigo in a child with atopic dermatitis.…”

Section: Bacterial Infectionsmentioning

confidence: 99%

“… 3 Infectious complications of AD include skin and soft tissue infections (SSTI), eczema herpeticum (EH), bacteremia, osteomyelitis, septic arthritis, and endocarditis. 4 These complications lead to significant financial burden on the health care system. 5 In this review, we will summarize the advances in the mechanisms, clinical complications, and management of infections in AD.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The infectious complications of atopic dermatitis

Wang

Boguniewicz

et al. 2021

Annals of Allergy, Asthma & Immunology

Self Cite

114

View full text Add to dashboard Cite

Objective Atopic dermatitis (AD) is a chronic inflammatory skin disease that is complicated by an increased risk for skin and systemic infections. Preventive therapy for AD is based on skin barrier improvement and anti-inflammatory treatments, whereas overt skin and systemic infections require antibiotics or antiviral treatments. This review updates the pathophysiology, diagnosis, management, controversy of antibiotic use, and potential treatments of infectious complications of AD. Data Sources Published literature obtained through PubMed database searches and clinical pictures. Study Selections Studies relevant to the mechanisms, diagnosis, management, and potential therapy of infectious complications of AD. Results Skin barrier defects, type 2 inflammation, Staphylococcus aureus colonization, and cutaneous dysbiosis are the major predisposing factors for the increased infections in AD. Although overt infections require antibiotics, the use of antibiotics in AD exacerbation remains controversial. Conclusion Infectious complications are a comorbidity of AD. Although not common, systemic bacterial infections and eczema herpeticum can be life-threatening. Preventive therapy of infections in AD emphasizes skin barrier improvement and anti-inflammatory therapy. The use of antibiotics in AD exacerbation requires further studies.

show abstract

Section: Bacterial Infectionssupporting

confidence: 78%

Section: Bacterial Infectionsmentioning

confidence: 99%

Figure 2 Impetigo in a child with atopic dermatitis.…”

Section: Bacterial Infectionsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The infectious complications of atopic dermatitis

Wang

Boguniewicz

et al. 2021

Annals of Allergy, Asthma & Immunology

Self Cite

114

View full text Add to dashboard Cite

show abstract

“…Штаммы MRSA у госпитализированных выделяются уже с частотой 22-39%. При этом клиндамицин лидирует в числе антибиотиков, назначавшихся детям с обострениями атопического дерматита с частотой эмпирического назначения в 74% [65].…”

Section: современные характеристики резистентности стафилококков кожиunclassified

Evolving concepts and emerging solutions to the problem of staphylococcal infection in dermatology

Сергеев¹,

Burtseva²,

Сергеева³

2019

Immunopathol Allergol Infectol

View full text Add to dashboard Cite

Стафилококки входят в постоянный состав кожной микробиоты и могут вызывать различные инфекции кожи, играя роль и в развитии воспаления при хронических дерматозах. Новые сведения о взаимодействии стафилококков с разными микроорганизмами, кератиноцитами и иммунокомпетентными клетками расширяют наши представления о патогенезе пиодермий, атопического дерматита, акне и другой распространенной патологии кожи. Проблема нарастающей устойчивости стафилококков и, в частности, S. aureus, к наиболее активно используемым антибиотикам вызывает опасения за эффективность химиотерапии инфекций кожи и мягких тканей, в том числе инфекционных осложнений атопического дерматита. Многие ранее использовавшиеся в дерматологии препараты могут выйти из клинического обращения в силу широко распространившейся антибиотикорезистентности к ним в современной популяции. Одними из современных средств, рекомендованных в лечении пиодермии в нашей стране и за рубежом, являются препараты фузидовой кислоты. Проведенное нами в 2009-2019 гг. исследование показало, что в течение 10 лет частота выявления устойчивых к фузидовой кислоте стафилококков у 930 больных хроническими дерматозами выросла не более, чем на 4%, а свыше 90% изученных штаммов оказались чувствительными к препарату. С учетом полученных данных 2% крем и мазь фузидовой кислоты сегодня можно считать средствами первой линии в лечении пиодермии.

show abstract

The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and network meta-analysis

Alves

Penedones

Mendes

et al. 2022

Eur J Clin Pharmacol

View full text Add to dashboard Cite

Janus kinase (JAK) inhibitors have been developed to treat moderate to severe atopic dermatitis, but there is little evidence comparing the safety pro le of these drugs. The aim of this study is to compare the relative safety of the different systemic JAK inhibitors in atopic dermatitis. MethodsMedline, EMBASE and clinicaltrials.gov were searched to identify phase 2/3, clinical trials (RCTs) designed to evaluate the e cacy and safety of systemic JAK inhibitors in atopic dermatitis. Outcomes were the risk of any adverse event (AE), serious AEs, AEs leading to treatment discontinuation, any infection, serious infections, herpes viral infections and any cardiac or vascular event. ResultsEighteen RCTs were included. Compared with placebo, baricitinib (

show abstract

Antibiotic choice and methicillin-resistant Staphylococcus aureus rate in children hospitalized for atopic dermatitis

Cited by 27 publications

References 20 publications

The infectious complications of atopic dermatitis

The infectious complications of atopic dermatitis

Evolving concepts and emerging solutions to the problem of staphylococcal infection in dermatology

The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and network meta-analysis

Contact Info

Product

Resources

About